13 completed. 9 Phase 1, 4 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
| Phase 2 | 4 | Completed 4 |
| Not applicable | 2 | Completed 2 |
Follow Recurrent Basal Cell Carcinoma of the Lip: new trials by email Literature Review of Recurrent Basal Cell Carcinoma of the Lip trials Research Report on Recurrent Basal Cell Carcinoma of the Lip
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy acetylcysteine, placebo, quality-of-life assessment - Mucositis, Oral Complications | Phase 2 | Completed | Mayo Clinic | 34 | 2014-04-01 | 2019-04-30 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer quality-of-life assessment, management of therapy complications, L-lysine - Mucositis, Oral Complications of Chemotherapy | Not applicable | Completed | University of Washington | 10 | 2010-09-01 | 2013-05-17 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer bevacizumab, placebo, magnetic resonance imaging - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2007-06-01 | 2014-05-09 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
| Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer HPPH, photodynamic therapy, conventional surgery - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Roswell Park Cancer Institute | 15 | 2006-10-19 | 2022-07-25 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study - Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2004-07-01 | 2013-04-10 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer gefitinib - Anaplastic Thyroid Cancer, Insular Thyroid Cancer | Not applicable | Completed | National Cancer Institute (NCI) | 40 | 2003-08-01 | 2013-01-14 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction erlotinib hydrochloride, laboratory biomarker analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 75 | 2001-12-01 | 2013-01-16 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2001-12-01 | 2013-09-30 |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer hydroxyurea, fluorouracil, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 39 | 2001-07-01 | 2013-02-07 |
Salivary Gland Neoplasms (13) · Squamous Cell Carcinoma of Head and Neck (12) · Esthesioneuroblastoma, Olfactory (11) · Colonic Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Pancreatic Neoplasms (5) · Rectal Neoplasms (5) · Tongue Neoplasms (5) · Breast Neoplasms (4) · Anus Neoplasms (3) · Brain Neoplasms (3) · Breast Neoplasms, Male (3) · Carcinoma, Hepatocellular (3) · Carcinoma, Ovarian Epithelial (3) · Carcinoma, Renal Cell (3)
Carcinoma (13) · Head and Neck Neoplasms (13) · Mouth Diseases (13) · Neoplasms by Histologic Type (13) · Neoplasms by Site (13) · Neoplasms, Glandular and Epithelial (13) · Salivary Gland Diseases (13) · Stomatognathic Diseases (13) · Carcinoma, Squamous Cell (12) · Mouth Neoplasms (12) · Neoplasms (12) · Cranial Nerve Diseases (11) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Nerve Tissue (11) · Neoplasms, Neuroepithelial (11)
Bevacizumab (3) · Cetuximab (3) · Erlotinib Hydrochloride (3) · 1-phenyl-3,3-dimethyltriazene (1) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (1) · 7-hydroxystaurosporine (1) · Acetylcysteine (1) · Congresses as Topic (1) · Everolimus (1) · FPP(RGD)2 (1) · Filgrastim (1) · Fluorodeoxyglucose F18 (1) · Fluorouracil (1) · Gefitinib (1)
National Cancer Institute (NCI) (8) · Fox Chase Cancer Center (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · Sanjiv Sam Gambhir (1) · University of Washington (1)
United States (13)
Alain Mita (1) · Antonius Miller (1) · Barbara Burtness (1) · David Solit (1) · Everett Vokes (1) · Hassan Arshad (1) · Laura Goff (1) · Michele Halyard (1) · Monica Loghin (1) · Paula Fracasso (1) · Sanjiv Gambhir, MD, PhD (1) · Shirish Gadgeel (1) · Upendra Parvathaneni (1)
PMID 23868427, PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872, PMID 31405750
N01CM62202 (1), P30CA015083 (1), P30CA016672 (1), P30CA044579 (1), P30CA054174 (1), P30CA068485 (1), U01CA069853 (1), U01CA069856 (1), U10CA031946 (1), U10CA032102 (1)